Kübra Kılıç

Kübra Kılıç

Auto-generated profile, based on publicly available information

Kübra Kılıç

Department of Pharmaceutical Biotechnology, Gulhane Faculty of Pharmacy, University of Health Sciences, Ankara 06018, Türkiye

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GTGizem Ruya TOPAL
Gizem Ruya TOPAL
KKKubra Kilic
Kubra Kilic
MSMeral Sarper
Meral Sarper
OEOzgur Esim
Ozgur Esim
ASAyhan Savaser
Ayhan Savaser
YOYalcin Ozkan
Yalcin Ozkan
Objectives: Limited intracellular exposure can reduce the in vitro activity of pazopanib (PAZ) and enzalutamide (ENZ). This study developed bovine serum albumin (BSA) particles co-encapsulating PAZ and ENZ (PE-BSA) and evaluated physicochemical properties, release kinetics, 4T1 cellular uptake, and in vitro cytotoxicity versus free drugs and single-drug particles. Methods: Drug-loaded BSA particles were prepared using a crosslinking-based method. Particle size (PS), polydispersity index (PDI), zeta potential (ZP), and encapsulation efficiency (EE) were determined. In vitro release was assessed over 48 h and fitted to kinetic models. 4T1 uptake was quantified after 2 and 4 h by intracellular drug levels. Cytotoxicity was measured by MTT at 24 and 72 h (1–100 µg/mL). Moreover, cell death analyses were conducted. Stability studies at +4 °C and serum were also carried out. Results: PE-BSA was nanoscale and monodisperse (PS 128.7 ± 2.6 nm; PDI 0.026 ± 0.01) with ZP −31.65 ± 1.13 mV and high EE (PAZ 98.59 ± 1.78%; ENZ 69.79 ± 0.02%). At 24/48 h, cumulative release from PE-BSA was 11.96/12.31% for PAZ and 52.26/85.95% for ENZ. The release kinetics were best described by the Korsmeyer–Peppas model for PAZ (r2 = 0.9578) and the Higuchi model for ENZ (r2 = 0.9605), indicating diffusion-controlled release. PE-BSA increased 4T1 uptake versus free drugs (2 h: 10.02% PAZ and 21.9% ENZ; 1.77-fold and 4.15-fold), with sustained enhancement at 4 h (2.2- and 4.69-fold, respectively). After 24 h, PE-BSA induced a markedly higher apoptotic response in 4T1 cells (32.5% early apoptosis and 0.8% late apoptosis/early necrosis) compared with free-PAZ (6.6% early apoptosis) and P-BSA (7.3% early apoptosis). Particles were stable. Conclusions: PE-BSA produced BSA particles with diffusion-governed release and enhanced 4T1 internalization, supporting albumin particles as a delivery platform to increase intracellular exposure of PAZ/ENZ in vitro.

14 September 2026 in Molecules
Verified
Journal Article
Open access
PDF file
OAOkan Ali AKSOY
Okan Ali AKSOY
Yagmur OkcayYagmur Okcay
Yagmur Okcay
ASAlperen Enes Solmaz
Alperen Enes Solmaz
KKKübra Kılıç
Kübra Kılıç
BGBerk Alp GÖKSEL
Berk Alp GÖKSEL
YÖYalçın Özkan
Yalçın Özkan
Kahweol is an active diterpene with anti-inflammatory, antioxidant, and anticancer properties; however, its use may be limited by unfavorable pharmacokinetic characteristics. This study aimed to develop kahweol-loaded poly(lactic-co-glycolic acid) (PLGA) and red blood cell membrane-coated PLGA (RBC-PLGA) nanoparticles and evaluate their in vitro release behavior and in vivo pharmacokinetic profiles. Kahweol-loaded PLGA nanoparticles were prepared using the emulsification-solvent evaporation method and subsequently coated with rabbit erythrocyte membranes, a type of blood cell membrane, to obtain RBC-PLGA nanoparticles. Particle size, zeta potential, morphology, and encapsulation efficiency were characterized. In vitro release studies were performed using the dialysis bag method. Pharmacokinetic profiles of free kahweol, kahweol-loaded PLGA, and kahweol-loaded RBC-PLGA nanoparticles were evaluated in rabbits following intravenous administration (0.5 mg/kg), and plasma kahweol concentrations were analyzed by LC-MS/MS. PLGA and RBC-PLGA nanoparticles showed high encapsulation efficiency (>90%) and sustained biphasic release compared with the rapid burst release of free kahweol. Pharmacokinetic analysis demonstrated that PLGA and RBC-PLGA nanoparticles reduced peak plasma concentrations and prolonged systemic exposure. Among the nanoparticles, RBC-PLGA exhibited the most prolonged pharmacokinetic profile, with delayed time to maximum plasma concentration (Tmax), extended half-life, and increased overall exposure. The nanoparticles improved the pharmacokinetic profile of kahweol by enabling sustained release and prolonged systemic exposure, supporting their potential as delivery platforms for future applications.

31 August 2026 in Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
Verified
Journal Article
Closed access
Yıldırım CesaretliYıldırım Cesaretli
Yıldırım Cesaretli
BEBurcu Eser
Burcu Eser
EÇEsra Merve Zanbak Çotaoğlu
Esra Merve Zanbak Çotaoğlu
KKKübra Kılıç
Kübra Kılıç
An LC–MS/MS procedure was developed and evaluated for measuring vildagliptin in analytical standard solutions, with linagliptin serving as the internal standard. Reference materials dissolved in acetonitrile were used to produce the calibration and quality-control (QC) solutions, and six independently prepared placebo samples were examined for excipient-related interference. An ACE C18 column (50 mm × 2.1 mm, 5 µm) was operated under gradient conditions at 0.3 mL min⁻¹ with 10 mM ammonium acetate and acetonitrile as the aqueous and organic components; each contained 0.01% formic acid. Positive-ion electrospray and multiple-reaction monitoring were used for detection. Across the validated interval of 0.125–4.0 ng mL⁻¹, the calibration model gave R² = 0.9951. Instrumental LOD and LOQ values in the injected solutions were 0.028 and 0.084 ng mL⁻¹, respectively. The highest intra-day or inter-day precision value was 2.15% RSD. At the three QC levels, mean recovery was 99.12–101.7%, and recovery RSD was 2.00–3.29% (n = 6). Each chromatographic cycle lasted 7.5 min. No interfering vildagliptin MRM peak was detected in the placebo preparations, although ion suppression and enhancement were not measured quantitatively. The validation applies to prepared analytical solutions and does not establish performance in dosage forms or biological matrices.